Pfizer (PFE)
28.47
+0.00 (0.00%)
NYSE · Last Trade: Nov 18th, 7:10 AM EST
Detailed Quote
| Previous Close | 28.47 |
|---|---|
| Open | - |
| Bid | 28.25 |
| Ask | 28.30 |
| Day's Range | N/A - N/A |
| 52 Week Range | 23.62 - 31.44 |
| Volume | 37,903 |
| Market Cap | 159.62B |
| PE Ratio (TTM) | 40.67 |
| EPS (TTM) | 0.7 |
| Dividend & Yield | 1.720 (6.04%) |
| 1 Month Average Volume | 35,025,314 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
Pfizer Inc. (NYSE: PFE) today announced that it entered into an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines designed to enable in vivo therapeutics. Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialize three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs that are focused on treating autoimmune diseases. Pfizer also receives rights to use Starna’s proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology, as well as options to exclusively license compounds created under a separate research collaboration and an option to expand the territory to include exclusive rights to develop and commercialize each exclusively licensed compound and product in Greater China.
By Pfizer Inc. · Via Business Wire · November 18, 2026
Novavax (NASDAQ:NVAX) is looking to expand partnerships around its vaccine technology while advancing a potential C. difficile vaccine and supporting partner Sanofi’s development of a combination COVID-19 and flu shot, executives said at the Jefferies 2026 Global Healthcare Conference in London.
CE
Via MarketBeat · November 17, 2026
J&J's quarterly sales have climbed with few setbacks, while Pfizer's have swung between $13.7 billion and $17.8 billion over eight quarters.
Via The Motley Fool · November 17, 2026
S&P 500 Most Active Stocks for Nov. 17, 2026chartmill.com
Via Chartmill · November 17, 2026
Pfizer (NYSE:PFE) expects recently launched medicines and a growing pipeline to help it emerge from a period of patent expirations with high single-digit growth, CEO Albert Bourla said at the Jefferies London Healthcare Conference.
Bourla said the loss-of-exclusivity period is expected to last anot
Via MarketBeat · November 17, 2026
These two stocks can provide reliable income for your portfolio for years to come.
Via The Motley Fool · November 16, 2026
Today's Most-Active S&P 500 Stocks: Ford Leads Volume as SMCI and Micron Fallchartmill.com
Via Chartmill · November 16, 2026
A high yield is a sign that investors are worried about a business, but sometimes that concern is overwrought.
Via The Motley Fool · November 14, 2026
Novo Nordisk's obesity-drug dominance faces rising rivals, while Pfizer's cheaper valuation and cash flow tell a different story for income-minded investors.
Via The Motley Fool · November 14, 2026
Axsome's revenue has climbed about 54% while Moderna's net losses run deep, but a steep valuation gap may tip the scales for patient investors.
Via The Motley Fool · November 14, 2026
These healthcare dividend stocks appeal to investors in different ways.
Via The Motley Fool · November 14, 2026
Pfizer isn't out of the woods yet, but it is proving it remains a well-run drugmaker.
Via The Motley Fool · November 13, 2026
Stocks are finally settling down following a few weeks of extreme volatility. Use this lull as an entry point before more investors realize many of these names are currently on sale at a great price.
Via The Motley Fool · November 13, 2026
These catalysts could impact growth down the road.
Via The Motley Fool · November 13, 2026
Most Active S&P 500 Stocks: KDP, Ford, AT&T Lead Today's Sessionchartmill.com
Via Chartmill · November 12, 2026
Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences (“Blackstone”) today announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of $1.5 billion of development costs through 2028 for berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the funding, Blackstone will be eligible to receive milestone-based payments, subject to U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management, and achievement of certain commercial sales milestones.
By Pfizer Inc. · Via Business Wire · November 11, 2026
These three blue chip dividend stocks offer higher yields while standing out in terms of dividend coverage and growth.
Via The Motley Fool · November 10, 2026
These stocks pay as much as 5.9% in dividends.
Via The Motley Fool · November 10, 2026
S&P 500 Most Active Stocks in Today's Session: SMCI, AT&T, Ford Lead Volumechartmill.com
Via Chartmill · November 10, 2026
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Jefferies London Healthcare Conference on Tuesday, November 17, 2026 at 9:00 a.m. GMT.
By Pfizer Inc. · Via Business Wire · November 10, 2026
This surprising healthcare stock has been outperforming the markets this year.
Via The Motley Fool · November 10, 2026
A SkinJect SPAC plan and melanoma focus mark the next phase.
Via The Motley Fool · November 9, 2026
Most-Active S&P 500 Stocks in Today's Sessionchartmill.com
Via Chartmill · November 9, 2026
Investors shouldn't count out Pfizer in the GLP-1 market just yet.
Via The Motley Fool · November 9, 2026
November 8, 2026 -- November 13–15 Virtual Event Connects Caregivers, Healthcare Professionals, and Advocates Across Borders
Via 24-7 Press Release · November 8, 2026